Octapharma highlights efficacy of Octanate at symposium

Octapharma has highlighted the potential benefits its human plasma-derived, von Willebrand factor-containing FVIII concentrate Octanate can deliver to haemophilia patients at an international symposium.

The company sponsored the Inhibitors in Haemophilia A: Prevention, Current Management and Personalised Therapy Perspectives presentation at the World Federation of Haemophilia's yearly congress, during which it reported study data supporting Octanate's efficacy.

Results from several trials underlined the product's effectiveness in re-establishing haemostasis by eradicating FVIII inhibitors, helping patients to achieve complete treatment success and improve their quality of life.

Dr Olaf Walter, head of Octapharma's haematology business unit, said the presentations were designed to help highlight the importance of combating FVIII antibody inhibitors.

He explained: "The development of FVIII antibody inhibitors during FVIII replacement is the most significant medical complication today in the life-long treatment of haemophilia."

Earlier this month, the company announced that it has commenced phase II/III testing of a new immunoglobulin therapy for sufferers of chronic inflammatory demyelinating polyradiculoneuropathy.